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Abstract
Objective
Osteoporotic fragility fractures, that are common in men and women, signal increased risk
of future fractures and of premature mortality. Less than one-third of postmenopausal
women and fewer men are prescribed active treatments to reduce fracture risk. Therefore,
in this study the association of oral bisphosphonate recommendation with subsequent frac-
ture and mortality over eight years in a fracture liaison service setting was analysed.
Materials and methods
In this prospective cohort study, 5011 men and women aged >50 years, who sustained a
clinical fracture, accepted the invitation to attend the fracture liaison service of the West
Glasgow health service between 1999 and 2007. These patients were fully assessed and all
were recommended calcium and vitamin D. Based on pre-defined fracture risk criteria, 2534
(50.7%) patients were additionally also recommended oral bisphosphonates. Mortality and
subsequent fracture risk were the pre-defined outcomes analysed using Cox proportional
hazard models.
Results
Those recommended bisphosphonates were more often female (82.9 vs. 72.4%), were older
(73.4 vs. 64.4 years), had lower bone mineral density T-score (-3.1 vs. -1.5) and more had
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sustained hip fractures (21.7 vs. 6.2%; p < 0.001). After adjustments, patients recommended
bisphosphonates had lower subsequent fracture risk (Hazard Ratio (HR): 0.60; 95% confi-
dence interval (CI): 0.49–0.73) and lower mortality risk (HR: 0.79, 95%CI: 0.64–0.97).
Conclusion
Of the patients, who are fully assessed after a fracture at the fracture liaison service, those
with higher fracture risk and a recommendation for bisphosphonates had worse baseline
characteristics. However, after adjusting for these differences, those recommended bis-
phosphonate treatment had a substantially lower risk for subsequent fragility fracture and
lower risk for mortality. These community-based data indicate the adverse public health out-
comes and mortality impacts of the current low treatment levels post fracture could be
improved by bisphosphonate recommendation for both subsequent fracture and mortality.
Introduction
Osteoporotic fragility fractures are common in men as well as women. More than 50% of
women and more than 25% of men aged older than 50 years will sustain a fragility fracture in
their remaining lifetime.[1–4] Moreover, it is clear that initial fragility fractures signal substan-
tially increased risk of further fractures.[5, 6] Several data also support the relationship
between major (proximal) fragility fractures and premature mortality.[7–21] Secondary frac-
ture prevention, using pharmacological treatments for osteoporosis, happens relatively rarely
for women and even more rarely for men. Although it is validated in randomised controlled
trials (RCTs) and endorsed by all national guidelines.[5, 22, 23] Worldwide, there is a rising
call for implementing fracture liaison services for secondary fracture prevention.[5, 22, 23] A
recent review [24] reported improvement of treatment of postmenopausal US women after a
fracture, but this still occurred in less than 30%. Men do worse after such fractures in terms of
future fracture risk and in terms of excess mortality.[6–10, 16, 20] In some jurisdictions, the
lack of implementation may relate to concerns about the robustness of evidence for the clinical
and societal benefit in the “real world”. Recent studies of osteoporosis pharmacotherapy have
reported statistically and clinically significant survival benefits in one RCT,[25] a meta-analysis
of prior RCTs,[26] and population-based studies.[27, 28] It is suggested that RCTs of fracture
liaison services after prior fractures are required to evaluate fracture risk reduction and sur-
vival effects in the general community. However, such trials are unlikely given the major ethi-
cal challenges of randomising some participants to less than recommended care.[29]
For that reason, the risk of subsequent fractures and mortality over an 8-year follow-up
period was evaluated in patients with fractures attending the West Glasgow Fracture Liaison
Service in relation to recommendations for osteoporosis specific therapy.
Materials and methods
Study design and participants
Between 1999 and 2007, patients aged 50 years and over with a low trauma fracture at accident
& emergency/trauma and orthopaedic fracture services were identified by osteoporosis nurse
specialists of the Fracture Liaison Service of the West Glasgow health service, as previously
described.[30, 31] Low trauma was defined as no obvious cause or minimal trauma such as a
fall from standing height or less.
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Patients were assessed approximately six weeks post fracture. Treatment was typically
started around two weeks later by the patient’s general practitioner (GP). [30, 31] Treatment
was recommended for five years in first instance and GPs were advised to arrange DXA moni-
toring after that interval. [30] Eight years later, patients were followed up to see whether they
had sustained any subsequent fractures and whether they were still alive. All fractures were
radiographically confirmed. Deaths were confirmed by hospital records, which were updated
quarterly from the records of the office of the Scottish registrar of deaths. Specific adherence
data are not available.
Exposure
For those attending the Fracture Liaison Service, a treatment recommendation based on pre-
defined criteria related to assessment of future potential fracture risk and endorsed by the lead
consultant was provided to the patient’s general practitioner. All patient data with regard to
fracture and medical history, risk factors for osteoporosis and fractures, lifestyle, (and if indi-
cated) osteoporosis treatment recommendations, and arrangements for follow-up were stored
in a computerised database.[30, 31] Blood samples were collected to exclude secondary osteo-
porosis.[32] All patients who had such potential causes identified were recommended appro-
priate treatments as per national guidelines.
All attendees were recommended oral 1000 mg calcium, as carbonate, and 800 IU vitamin D
daily reflecting the regimen by Chapuy et al.[33] Patients, meeting pre-specified criteria also
had oral bisphosphonate therapy recommended.[30] Oral bisphosphonate therapy was identi-
fied as the treatment of choice and recommended in accordance with evidence-based practice
and national osteoporosis guidelines at that time, unless there was a clear contraindication.[30]
It was recommended based on the following predefined criteria: site (and number) of fractures
and lowest T-score at femoral neck, total hip or lumbar spine according to the patient’s age.
Patients aged 50 years or older were recommended oral bisphosphonate if they had had:
• two or more vertebral fractures irrespective of patient’s age or bone mineral density (BMD)
T-score, or
• only one prior vertebral fracture and BMD -2.0 (age 50–59 years) or -1.6 (aged 60
years), or
• any other prior non-vertebral fracture & BMD -2.5 (age 50–59 years) or -2.0 ( 60
years).
Note that in order to receive a bisphosphonate recommendation, patients did not need to
have an osteoporotic T-score ( -2.5).
Main outcome measures and covariates
Mortality and subsequent fracture rates were the pre-defined outcomes. The following baseline
characteristics were included in the analyses: gender, age, weight, height, body mass index
(BMI), femoral neck and lumbar spine BMD T-score, initial fracture type: hip, major (pelvis,
distal femur, proximal tibia, multiple rib, proximal humerus, clinical vertebra) or minor (all
other). These major and minor fracture groupings were chosen as they had been previously
shown to relate to mortality outcomes.[34] Also included were recognised health conditions
and co-morbidities, such as: smoking status, past or current glucocorticoid use, presence of
rheumatoid arthritis, inflammatory bowel disease, family history of osteoporosis, a maternal
history of hip fracture, thyrotoxicosis and alcohol intake 5 units/day. Note that this criterion
for alcohol excess pre-dated the FRAX1 categorisation and was unequivocally excessive.
Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation
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Statistical analyses
The analyses in this paper are focused on those patients, who accepted the invitation for full
assessment. Therefore, the data presented are only for those subjects who attended the FLS
clinic and received bisphosphonate treatment recommendations (or not) based on pre-defined
criteria. The outcomes of subsequent fractures and mortality over an 8-year follow-up period
was analysed using SPSS (version 21.0). Those patients recommended oral bisphosphonates
(plus calcium and vitamin D) were compared with those who were recommended calcium and
vitamin D alone. A small number (2.5%) of individuals recommended hormone therapy (HT),
strontium ranelate or teriparatide, were excluded.
Some individuals did not receive the pre-defined recommendations; i.e. were recommended
bisphosphonate when they did not meet the criteria or did not receive that recommendation
when they did meet them. These individuals were assessed both according to recommendations
given (primary analyses) and to the pre-defined criteria (sensitivity analyses).
Primary analyses
Firstly, independent sample T-test and Chi-square tests were performed to compare baseline
characteristics of patients who were recommended oral bisphosphonates (plus calcium and
vitamin D) versus those who were recommended calcium and vitamin D alone (Table 1).
Table 1. Characteristics of patients prescribed oral bisphosphonates compared with those prescribed only calcium and vitamin D.
Vitamin D and calcium alone (n = 2477) Bisphosphonates plus vitamin D and calcium (n = 2534) P-value
Gender, n (%) < 0.001
Women 1793 (72.4) 2100 (82.9)
Men 684 (27.6) 434 (17.1)
Age, mean (SD) years 64.4 (10.2) 73.4 (9.3) < 0.001
Weight, mean (SD), kg a 75.9 (16.5) 62.8 (12.9) < 0.001
Height, mean (SD), cm a 163 (8.4) 157 (8.0) < 0.001
Body mass Index, mean (SD), kg/m2 a 28.7 (5.8) 25.4 (4.7) < 0.001
Lowest T-score, mean (SD) b -1.5 (0.96) -3.1 (0.76) < 0.001
T-score Femoral Neck, mean (SD) -1.2 (0.97) -2.5 (0.80) < 0.001
T-score Lumbar Spine, mean (SD) -1.1 (1.21) -2.8 (1.03) < 0.001
Initial fracture type, n (%)c < 0.001
Hip 154 (6.2) 551 (21.7)
Major 513 (20.7) 620 (24.5)
Minor 1810 (73.1) 1363 (53.8)
Alcohol intake 5 units/day, n (%) 258 (10.4) 216 (8.5) 0.02
Smoking, n (%) 675 (27.3) 700 (27.6) 0.767
Past or current glucocorticoids, n (%) 47 (1.9) 71 (2.8) 0.04
Rheumatoid Arthritis, n (%) 26 (1.0) 68 (2.7) < 0.001
Inflammatory Bowel Disease, n (%) 24 (1.0) 19 (0.7) 0.400
Family history of osteoporosis, n (%) 287 (11.6) 333 (13.1) 0.10
Maternal history of hip fracture, n (%) 173 (7.0) 181 (7.1) 0.83
Thyrotoxicosis, n (%) 30 (1.2) 68 (2.7) < 0.001
a Height, weight and body mass index (BMI) data were available in 1739 (70%) of those not on bisphosphonates treatment and 1490 (59%) of those on bisphosphonates
treatment.
b T-score based on lowest value of BMD at lumbar spine or femoral neck sites.
c Hip, major (pelvis, distal femur, proximal tibia, multiple rib, proximal humerus, clinical vertebra) or minor (all other)
https://doi.org/10.1371/journal.pone.0198006.t001
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Secondly, the proportional hazard assumption checked using Schoenfeld residuals.
Tests were performed to check for interaction. If interaction was present, this was added
in the model. Univariable and multivariable Cox proportional hazard models were used.
All variables (Table 1) were considered in the univariable analysis. Different thresholds
for the P-value were used for inclusion in the multivariable analysis and for selection of
the final model:
(i) In univariable models, a P 0.10 was used for selection of potentially important covari-
ates to be included in the entry multivariable model, [35] and
(ii) In the multivariable model, the more stringent P 0.05 was used in the backward step-
wise approach for selection of independent predictors in the final multivariable model.
For the final multivariable models, the backward procedure was used, excluding variables above
a value of P> 0.05. All variables not stated in Tables 2 or 3, are excluded due to P-value> 0.05.
Table 2. Predictors of subsequent fractures. Multivariable Cox regression model; values are presented as hazard
ratios (HR) with 95% confidence intervals (95%CI).
Subsequent fractures HR (95%CI) p-value
Gender (women) 1.63 (1.29–2.05) <0.001
Increasing age (per 5 years) 1.06 (1.02–1.11) 0.011
Worse T-score (per 0.5 SD) a 1.19 (1.14–1.25) <0.001
Alcohol intake 5 units/day 1.98 (1.52–2.57) <0.001
Smoking 1.30 (1.08–1.55) 0.005
Bisphosphonates 0.60 (0.49–0.73) <0.001
a T-score based on lowest value of lumbar spine or femoral neck
https://doi.org/10.1371/journal.pone.0198006.t002
Table 3. Predictors of mortality. Multivariable Cox regression model; values are presented as hazard ratio’s (HR)
with 95% confidence intervals (95%CI).
Mortality HR (95%CI) p-value
Gender (women) 0.55 (0.46–0.67) <0.001
Increasing age (per 5 years) 1.42 (1.35–1.49) <0.001
Worse T-score (per 0.5 SD) a 1.10 (1.05–1.15) <0.001
Initial fracture b
Hip 1.46 (1.19–1.81) <0.001
Major 1.30 (1.07–1.58) 0.008
Minor Reference
Alcohol intake 5 units/day 1.70 (1.31–2.20) <0.001
Smoking 1.82 (1.51–2.19) <0.001
Past or current GC use c 1.87 (1.23–2.85) 0.003
Bisphosphonates 0.79 (0.64–0.97)d 0.022
a T-score based on lowest value of lumbar spine or femoral neck
b Hip, major (pelvis, distal femur, proximal tibia, multiple rib, proximal humerus, clinical vertebra) or minor (all
other)
c GC: glucocorticosteroids
d After including subsequent fractures in the model for mortality, the HR and 95%CI for bisphosphonates was
essentially unchanged (HR: 0.79 (0.64–0.97)
https://doi.org/10.1371/journal.pone.0198006.t003
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For mortality as a main outcome measure, time was defined as time to death or was cen-
sored at eight years of follow-up. Similarly for subsequent fracture, time was defined as time to
subsequent fracture or censored at eight years or death. In each analysis, gender specific analy-
ses were performed. Treatment (oral bisphosphonates (plus calcium and vitamin D) or cal-
cium and vitamin D alone) were analysed as co-variate.
Sensitivity analyses. Sensitivity analyses were performed for women and men analysed
separately. Also only patients who were correctly classified according to pre-defined criteria
were analysed, i.e. the other patients excluded.
Ethics statement
This was an evaluation of the outcomes of a clinical service that had been implemented and
commissioned by the National Health Service (NHS). Therefore, ethical approval was not
required.
AMcL was the developer and head of this first-in-the-world fracture liaison service and was
responsible for the development of the treatment criteria according to then existing guidelines.
He was thus involved in patient care delivery. Data was anonymized prior to access for any
analyses.
Results
A total of 5011 (53.1%) of 9439 men and women accepted the invitation to attend the
fracture liaison service and were fully assessed. The remaining 46.9% did not attend or
were not assessed, either because they were already receiving treatment (5.4%), were
considered by treating staff not to be candidates for further intervention beyond calcium
and vitamin D (19.3%) or too frail and infirm to attend or declined to attend (22.2%;
Fig 1).
Patient characteristics
The majority of the fully assessed patients (n = 5011) were either osteoporotic (45.5%) or
osteopenic (42.0%). Only 12.5% were found to have a normal BMD at all measured sites. Oral
bisphosphonates were recommended in 2534 patients (50.6%) based on the pre-defined crite-
ria of fracture type, age and lowest T-score, while 2477 patients were not recommended any
additional specific treatment, apart from calcium and vitamin D (Table 1).
Those recommended oral bisphosphonates were more likely to be women (82.9 vs.
72.4%). However, as expected based on the pre-defined criteria, they were older (73.4 vs.
64.4 years), had a lower BMI (25.4 vs. 28.7 kg/m2) and worse BMD T-score (-3.1 vs. -1.5)
and had had more ‘major’ fractures at baseline (21.7 vs 6.2% for hip, p < 0.001). They
reported significantly more rheumatoid arthritis, thyrotoxicosis (p < 0.001) or to have
used glucocorticoids (p = 0.035). Alcohol intake  5 units per day was a little more likely
in those who did not receive a recommendation for oral bisphosphonates (10.4 vs. 8.5%,
p = 0.022, Table 1).
Subsequent fractures
Patients who were recommended oral bisphosphonates had higher absolute subsequent frac-
ture risk (13.3% vs. 11.8%) over a mean follow-up of 40.9 vs. 42.7 months. However, given the
adverse criteria required to ‘trigger’ the recommendation for bisphosphonate use, they had a
higher underlying risk (Table 2). After adjustments for these adverse criteria, they had a signif-
icantly lower subsequent fracture hazard risk (HR: 0.60, 95%CI: 0.49–0.73; p< 0.001; Table 2
Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation
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and Fig 2A). There was no evidence of any interaction, and the Schoenfeld proportional haz-
ard assumption was not violated.
Mortality
Mortality was significantly higher in men, with increasing age, with more severe initial fracture
type, with lower BMD and with other co-morbidities, such as smoking, higher alcohol intake,
and corticosteroid use (Table 3). Again, given the adverse criteria to ‘trigger’ the recommenda-
tion for bisphosphonate use, these individuals had a higher underlying mortality risk. Consis-
tent with this adverse risk profile, absolute mortality was higher in the bisphosphonate-
recommended group 15.0% vs. 9.5% over a mean follow-up time of 44.9 vs. 46.4 months. How-
ever, after adjustment for the adverse risk profile (Table 3), treatment recommendation was
associated with a significantly lower mortality hazard (HR: 0.79: 0.64–0.97; p = 0.021; Table 3
and Fig 2B). There was no evidence of any interaction, and the Schoenfeld proportional hazard
assumption was not violated.
Fig 1. Patient disposition. All patients with low trauma fractures were invited to attend the Fracture Liaison service
clinics excluding those already on treatment, considered unsuitable for treatment and/or too frail and elderly and/or
declined to attend. The data and analyses herein relate to those who attended and were fully assessed. Re-fx:
Subsequent fracture.
https://doi.org/10.1371/journal.pone.0198006.g001
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Sensitivity analyses
Women and men analysed separately. For women, the absolute subsequent fracture risk
was not significantly higher for those who were recommended bisphosphonates (n = 2100;
14.0%) compared with those who were recommended calcium and vitamin D alone (n = 1793;
12.9%; p = 0.356). However, the absolute mortality risk was significantly higher (13.9% vs.
7.5%; p< 0.001). As mentioned above, women who were recommended bisphosphonates had
a significantly lower subsequent fracture risk (HR: 0.59, 95%CI: 0.47–0.74; p< 0.001). The
mortality risk was lower, albeit not significantly so (HR: 0.88, 95%CI: 0.69–1.13; p = 0.333).
For men, the absolute subsequent fracture risk was not significantly higher for those who
were recommended bisphosphonates (n = 434; 9.9%) compared with those who were recom-
mended calcium and vitamin D alone (n = 684; 8.9%; p = 0.579). The absolute mortality risk
was significantly higher (20.7% vs. 14.8%; p = 0.010). However, after the same adjustments as
mentioned above for fracture and mortality risk factors, men who were recommended bis-
phosphonates had a borderline lower subsequent fracture risk (HR: 0.66, 95%CI: 0.40–1.08;
p = 0.097), but mortality risk was significantly lower (HR: 0.67, 95%CI: 0.46–0.97; p = 0.035).
Only correctly classified patients according to pre-defined criteria. Of the 5011
patients, the recommendations for 4370 patients were according to the pre-defined criteria.
Other patients were excluded from these analyses. The absolute subsequent fracture and mor-
tality risk were significantly higher for those who were recommended bisphosphonates
(n = 2416; 13.2% and 15.1%, respectively) compared with those who were recommended cal-
cium and vitamin D alone (n = 1954; 9.0% and 7.4%, respectively; p< 0.001). After the same
adjustments, those who were recommended bisphosphonates had a lower, but not significantly
lower, subsequent fracture risk (HR: 0.88, 95%CI: 0.64–1.21; p = 0.432). However, the mortal-
ity risk (HR: 0.72, 95%CI: 0.52–0.98; p = 0.038) remained significantly lower.
Fig 2. Survival curves for subsequent fractures and mortality. The curves are based on multivariable Cox proportional hazard models for subsequent
fractures and mortality expressed as (A) fracture-free probability and (B) cumulative survival. Results presented for vitamin D and calcium
recommendation alone (dotted black) and for bisphosphonates plus calcium and vitamin D recommendation (solid grey).
https://doi.org/10.1371/journal.pone.0198006.g002
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Discussion
Patients who were recommended oral bisphosphonates had a significantly lower adjusted mor-
tality hazard 0.79 (0.64–0.97) and subsequent fracture risk 0.60 (0.49–0.73) compared with
those recommended calcium and vitamin D alone. Amongst these fully assessed patients
those, who attended the FLS and were recommended oral bisphosphonates had worse baseline
characteristics with respect to age, BMD and initial fracture severity, compared to those who
attended the same FLS in the same time line, but did not meet the pre-specific criteria. This
was expected based on the pre-defined criteria for a recommendation for bisphosphonate
treatment. Adjusting for these adverse baseline conditions, the observed mortality and subse-
quent fracture outcomes of the group who was recommended oral bisphosphonates were sig-
nificantly lower than in the group who was recommended calcium and vitamin D alone. The
survival benefit was independent of the relative fracture risk reduction. The present study sug-
gests that it is beneficial for patients who have sustained a fracture to receive oral bisphospho-
nate treatment in order to reduce their risk of further fractures and, importantly, reduce
premature mortality.
The sensitivity analyses generated similar findings were present in both men and women
and limiting the analyses to those who meet the predefined criteria. There were no changes in
the direction or estimated effect sizes but some changes in significance, presumably due to the
smaller numbers in these analyses.
Findings relative to previous studies
This finding is consistent with other population-based data,[36] one RCT [25, 37] and a meta-
analysis of specific anti-osteoporosis treatments.[26] The lower mortality risk in this study
(HR: 0.79) is similar to that observed in the zoledronic acid trial (HR: 0.72) and the Danish
health data analysis (HR 0.73).[25, 38] Each of these studies focuses on patients who had sus-
tained a recent fracture.
There is no clear mechanism defined for the mortality benefits in this cohort study or in the
other studies.[21, 25], [38] Possible mechanisms proposed, including reduced rate of bone loss
that has been shown in long term studies to be an independent predictor of mortality.[18, 39,
40] Interestingly, in the Danish study, the benefit was greater, albeit but not significantly so, in
those who filled multiple prescriptions (HR 0.73 vs. 0.84).
Limitations
At the time of this study, there were limited data on the efficacy of therapy in older individuals
particularly after hip fractures. Thus these elderly infirm subjects were not referred to the FLS.
These patients were expected to have a life expectancy of<6 months based on the judgment of
the physician. Also, some individuals declined to attend. A relatively small number of patients
was already on treatment and could therefore not be analysed as part of this comparison.
This study is an association study. Typical biases in observational studies, such as healthy
user effect and immortal time bias, were avoided in this study by limiting the analysis to those
people who attended the FLS clinic and were fully assessed. In this observational study, there is
no formal information on uptake of and adherence to bisphosphonate therapy. It is widely
understood that GPs and their patients respect the FLS and follow treatment recommenda-
tions. In any case, poor adherence would probably bias against seeing any association. On the
other hand, it is possible that patients recommended bisphosphonates received other medical
interventions from their GP that produced a benefit. However, since the criteria for treatment
recommendations were pre-defined and analyses were not based on adherence to therapy,
Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation
PLOS ONE | https://doi.org/10.1371/journal.pone.0198006 June 1, 2018 9 / 13
healthy complier and immortal time biases that confound analysis of treatment adherence per
se are avoided.
Strengths
The present study is the first that uses long-term real-world follow-up data of a large cohort
across a range of post-low trauma fractures. Importantly, as distinct for typical RCT
approaches in individuals with osteoporosis, this is the first study that uses the FLS approach
and limits analyses to people shortly after their fracture event presentation. The only compara-
ble study is that using zoledronic acid after hip fracture.[22, 28, 41, 42] Importantly the present
analyses were limited to people who attended the Fracture Liaison Service clinic within two
months of their fracture event presentation. This unique feature of all individuals being FLS
assessed within a few weeks of their fracture event focuses on the time of highest risk post frac-
ture and thus the group in whom treatment is likely to have its largest effect, as for the zoledro-
nic acid post-hip fracture study.[22, 28, 41, 42]
Strengths of this study include the criteria for treatment recommendations were specific,
pre-defined and were recorded for all individuals. Moreover, the long-term follow-up of the
individual patients is an advantage as randomized clinical trials rarely have any ‘placebo’ con-
trol group extending to this duration. Another strength of this study is that it extends the mor-
tality risk reduction findings not only to a longer time period and not only after hip fractures,
[43] but also to a wider range of fragility fractures.
Conclusion
In the context of systematic care and full assessment, these data indicate that a recommenda-
tion for specific osteoporosis treatment with oral bisphosphonates is likely to be beneficial by
reducing the predicted increased risk of subsequent fracture and by improving overall
survival.
While some studies have reported a reduction of mortality and subsequent fracture risk
reduction related to care in before-after implementation studies,[22, 28, 41, 42] it remained to
be shown whether concurrent improvements in treatment rates translate to real world
improvements in health outcomes. Thus, in the present study, in which allocation to specific
osteoporosis treatment recommendation (or not) was according to pre-defined criteria and
follow-up during the same time period, there was a benefit in survival as well as reduction in
subsequent fracture rates.
These findings indicate both fracture risk and survival benefits of pharmacotherapy for
osteoporosis accrue in those at high risk soon after a prior low trauma fractures. Currently,
only about one third of women and likely a smaller proportion of men are recommended spe-
cific anti-osteoporosis therapy even after a low trauma fracture.[24] The current findings indi-
cate that treatment recommendation according to guidelines for individuals who have suffered
fragility fractures has potentially benefits in terms of reduction in subsequent fracture and pre-
mature mortality.
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